Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
<p><strong>Background</strong> The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-...
Main Authors: | Voysey, M, Costa Clemens, SA, Madhi, SA, Folegatti, PM, Aley, PK, Angus, B, Bibi, S, Cicconi, P, Clutterbuck, EA, Dold, C, Emary, KRW, Ewer, KJ, Flaxman, A, Feng, S, Green, CM, Greenland, M, Jenkin, D, Joe, CCD, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, Y, Phillips, DJ, Plested, E, Ramasamy, M, Ritchie, AJ, Robinson, H, Song, R, Snape, MD, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ |
---|---|
Other Authors: | Oxford COVID Vaccine Trial Group |
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2021
|
Similar Items
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
by: Emary, KRW, et al.
Published: (2021) -
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Marchevsky, NG, et al.
Published: (2022) -
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
by: Voysey, M, et al.
Published: (2023) -
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
by: Clemens, SAC, et al.
Published: (2021) -
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
by: Flaxman, A, et al.
Published: (2021)